• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>Corcept Therapeutics

Corcept Therapeutics

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  1. Cortendo AB: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

    Cortendo AB: First Patient Enrolled into NormoCort Phase 3 SONICS Trial Following a Successful EU Investigator Meeting

  2. Berkshire's Second-Quarter Results on Target

    Noninsurance operations continue to be a source of stability, while its insurance business overall may see more meager results during the next couple of years.

  3. Cortendo Appoints Matthew Pauls as Chief Executive Officer

    Cortendo Appoints Matthew Pauls as Chief Executive Officer

  4. A Young Power Couple's Kickstart Portfolio

    With "massive" student debt loads receding in the rearview mirror, a young professional couple fires up their investment plan.

  5. Berkshire Starts Out 2014 on a Weaker Note

    Just about every segment at Berkshire was dealing with elevated costs during the first quarter.

  6. How We Value Berkshire Hathaway

    Alternative methods have some use, but we think discounted cash flow is the most fundamentally sound way to value the conglomerate, as we discuss in the final installment of our 5-part series.

  7. Why Berkshire's Moat Isn't Going Away Anytime Soon

    Morningstar's Gregg Warren says Berkshire's sterling balance sheet, strong business, and unique structure will sustain the firm's competitive standing--even without Buffett.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.